# HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

> **NCT06595563** · PHASE2 · RECRUITING · sponsor: **Jules Bordet Institute** · enrollment: 87 (estimated)

## Conditions studied

- HER2-positive Metastatic Breast Cancer
- HER2-positive Advanced Breast Cancer

## Interventions

- **DRUG:** Trastuzumab emtansine

## Key facts

- **NCT ID:** NCT06595563
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-03
- **Final completion:** 2029-09
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06595563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06595563, "HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-08-09 from https://api.ai-analytics.org/clinical/NCT06595563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*